Sign in

CIK 0001740279

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

IN8BIO, INC.

Sign in to watch
Ticker
INAB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
825462585
Phone
+1 646-600-6438
Business address
EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY, 10118
Former names
Incysus Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2021-08-03 FAIRBAIRN EMILY Director Conversion · Series A Preferred Stock −2,930,332 0
2021-07-29 Whitfill Travis Director Grant or award · Stock Option (right to buy) +10,500 10,500
2021-07-29 Roemer Alan S. Director Grant or award · Stock Option (right to buy) +10,500 10,500
2021-07-29 McCall Patrick Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +40,000 40,000
2021-07-29 Lamb Lawrence EVP and CSO Grant or award · Employee Stock Option (right to buy) +61,500 61,500
2021-07-29 Ho William Tai-Wei President, CEO and CFO Grant or award · Employee Stock Option (right to buy) +220,500 220,500
2021-07-29 Greenwood Luba Director Grant or award · Stock Option (right to buy) +21,000 21,000
2021-07-29 FAIRBAIRN EMILY Director Grant or award · Stock Option (right to buy) +21,000 21,000
2021-07-29 Brandt Peter C. Director Grant or award · Stock Option (right to buy) +10,500 10,500

Page 16 of 16 · 309 trades